Alnylam Pharmaceuticals, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2008 | -13.0% | -13.0% | — |
| FY2009 | -26.7% | -26.7% | -9.9% |
| FY2010 | -27.5% | -27.5% | -11.1% |
| FY2011 | -48.9% | -48.9% | -20.4% |
| FY2012 | -79.1% | -79.1% | -36.9% |
| FY2013 | -33.0% | -33.0% | -21.2% |
| FY2014 | -38.5% | -38.5% | -33.4% |
| FY2015 | -22.9% | -22.9% | -20.9% |
| FY2016 | -44.6% | -44.6% | -32.5% |
| FY2017 | -27.8% | -27.8% | -24.6% |
| FY2018 | -58.5% | -58.5% | -48.4% |
| FY2019 | -61.6% | -61.6% | -37.0% |
| FY2020 | -84.5% | -84.5% | -25.2% |
| FY2021 | -145.0% | -145.0% | -23.4% |
| FY2022 | 714.9% | 714.9% | -31.9% |
| FY2023 | 199.5% | 199.5% | -11.5% |
| FY2024 | -414.6% | -414.6% | -6.6% |
| FY2025 | 39.8% | 39.8% | 6.3% |